Tirzepatide vs Semaglutide
Which GLP-1 Is Right for You?
Tirzepatide and semaglutide are the two most widely discussed GLP-1 medications for weight loss and type 2 diabetes management. Both have demonstrated significant results in clinical trials, but they work through different mechanisms and come with distinct profiles for efficacy, side effects, and cost. This guide breaks down the evidence so you can have an informed conversation with your provider about which one may be the better fit for your goals.
How They Work: GLP-1 vs Dual GIP/GLP-1
The core difference between these two medications is their mechanism of action. Understanding this helps explain why clinical outcomes can differ.
Semaglutide (Ozempic, Wegovy)
Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your body naturally produces after eating. This slows gastric emptying, reduces appetite, and improves insulin secretion. It targets a single receptor pathway and has been studied extensively since its FDA approval for diabetes (Ozempic, 2017) and weight management (Wegovy, 2021).
- Single-receptor mechanism (GLP-1 only)
- Manufactured by Novo Nordisk
- Weekly subcutaneous injection
- Available as brand-name (Ozempic/Wegovy) and compounded formulations
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide is a dual GIP/GLP-1 receptor agonist, the first in its class. In addition to activating GLP-1 receptors like semaglutide, it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. Research suggests this dual action may provide additive benefits for appetite suppression, blood sugar regulation, and fat metabolism.
- Dual-receptor mechanism (GIP + GLP-1)
- Manufactured by Eli Lilly
- Weekly subcutaneous injection
- Available as brand-name (Mounjaro/Zepbound) and compounded formulations
Weight Loss Comparison
Both medications have shown impressive weight loss results in large-scale clinical trials. The data below reflects outcomes from their respective pivotal trial programs. Note that trial populations and designs differ, so direct comparisons should be interpreted with caution.
| Semaglutide 2.4 mg | Tirzepatide 15 mg | |
|---|---|---|
| Trial Program | STEP trials | SURMOUNT trials |
| Avg. Weight Loss | ~15-17% body weight | ~20-25% body weight |
| Timeline | 68 weeks | 72 weeks |
| Population | Adults with obesity or overweight + comorbidity | Adults with obesity or overweight + comorbidity |
| 5%+ Weight Loss | ~86% of participants | ~91% of participants |
Key Takeaway
Clinical trial data suggests tirzepatide may produce greater average weight loss at the highest doses. However, both medications deliver clinically meaningful results, and individual responses vary. Some patients respond exceptionally well to semaglutide while seeing less benefit from tirzepatide, and vice versa. Your provider can help determine which starting point makes the most sense based on your medical history.
Side Effects Comparison
Both medications share a similar side-effect profile, primarily gastrointestinal. Side effects are generally most pronounced during the titration phase and tend to improve as your body adjusts.
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | Common (~20-44%) | Common (~12-33%) |
| Diarrhea | Common (~15-30%) | Common (~12-23%) |
| Vomiting | Common (~5-24%) | Common (~5-13%) |
| Constipation | Common (~5-24%) | Common (~6-11%) |
| Injection site reactions | Uncommon | Uncommon |
| Discontinuation rate (GI) | ~4-7% | ~3-7% |
Studies suggest that GI side effects occur at broadly similar rates for both medications, though some trial data indicates slightly lower nausea rates with tirzepatide at comparable efficacy levels. Both medications carry boxed warnings regarding thyroid C-cell tumors observed in rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not use either medication.
Dosing & Titration
Both medications follow a titration approach, starting at a low dose and gradually increasing to minimize side effects and find the effective maintenance dose.
Semaglutide Titration
- Starting dose: 0.25 mg weekly (4 weeks)
- Step up: 0.5 mg weekly (4 weeks)
- Step up: 1.0 mg weekly (4 weeks)
- Step up: 1.7 mg weekly (4 weeks)
- Maintenance: 2.4 mg weekly (Wegovy protocol)
- Total titration to max dose: approximately 16-20 weeks
Tirzepatide Titration
- Starting dose: 2.5 mg weekly (4 weeks)
- Step up: 5 mg weekly (4 weeks)
- Step up: 7.5 mg weekly (4 weeks)
- Step up: 10 mg weekly (4 weeks)
- Step up: 12.5 mg weekly (4 weeks)
- Maintenance: up to 15 mg weekly
- Total titration to max dose: approximately 20-24 weeks
Important Note
Not everyone needs to titrate to the maximum dose. Many patients find an effective maintenance dose at a mid-range level. Your provider should adjust the schedule based on your response, tolerability, and goals. Faster titration increases the risk of GI side effects.
Cost & Availability
Cost is one of the biggest factors in choosing between these medications. Here is how they compare as of early 2026.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand-Name Retail | ~$1,000-1,400/mo | ~$1,000-1,200/mo |
| Compounded (Telehealth) | ~$149-349/mo | ~$199-449/mo |
| Insurance Coverage | Varies (more plans cover Ozempic for diabetes) | Varies (Mounjaro coverage expanding) |
| Manufacturer Savings | Novo Nordisk savings card (eligible patients) | Lilly savings card (eligible patients) |
| Supply Status | Intermittent shortages (some doses) | Generally more available |
Compounded versions of both medications are available through telehealth providers while FDA drug shortage designations remain in effect. The regulatory landscape around compounding is evolving, so check the FDA drug shortage database for the latest status.
Which One Is Right for You?
There is no universally "better" medication. The right choice depends on your medical history, goals, budget, and how your body responds. Here is a decision framework to discuss with your provider.
Consider semaglutide if...
- You want a medication with a longer clinical track record and extensive published data
- Your insurance covers Ozempic or Wegovy, making brand-name affordable
- You are looking for the lowest-cost compounded option to start
- You prefer starting with a single-receptor approach before trying a dual agonist
- Your provider recommends it based on your metabolic profile
Consider tirzepatide if...
- Maximizing weight loss is your primary goal and you want the dual-mechanism approach
- You have tried semaglutide and plateaued or did not see adequate results
- Your insurance covers Mounjaro or Zepbound
- You have type 2 diabetes and want the potential additive blood sugar benefits of GIP activation
- Your provider recommends it based on your metabolic profile and treatment history
A Note on Medical Guidance
This guide is for informational purposes and is not medical advice. Both tirzepatide and semaglutide are prescription medications that require evaluation by a licensed healthcare provider. Your provider will consider your full medical history, current medications, and individual risk factors when making a recommendation.
Ready to Compare Providers?
Once you know which medication you want to pursue, the next step is finding the right telehealth provider. We compared pricing, pharmacy quality, medical oversight, and more.
FAQ
Is tirzepatide more effective than semaglutide for weight loss?
Head-to-head clinical trials suggest that tirzepatide may produce greater average weight loss than semaglutide at comparable treatment durations. In the SURMOUNT and SURPASS trial programs, participants on the highest tirzepatide doses lost up to 20-25% of body weight, compared to roughly 15-17% in semaglutide trials like STEP. However, individual results vary significantly based on dose, adherence, diet, and exercise.
Can I switch from semaglutide to tirzepatide (or vice versa)?
Yes, switching between the two is possible under medical supervision. Your provider will typically start tirzepatide at the lowest dose (2.5 mg) even if you were on a higher semaglutide dose, since the medications work through different receptor pathways. Discuss your current dose and treatment history with your prescriber before making a change.
Do tirzepatide and semaglutide have the same side effects?
Both medications share common GI side effects: nausea, vomiting, diarrhea, and constipation are the most frequently reported. Clinical trial data suggests the overall rates are broadly similar, though some patients report that one is more tolerable than the other. Side effects tend to be worst during dose increases and often improve over time.
Which is cheaper, tirzepatide or semaglutide?
Without insurance, brand-name tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) are both in the $1,000-1,400/month range. Compounded versions through telehealth providers typically range from $149-399/month for either medication. Insurance coverage varies, so check your specific formulary. Manufacturer savings programs may also reduce costs.
Can I take tirzepatide or semaglutide without a diabetes diagnosis?
Yes. Semaglutide has FDA-approved formulations for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Tirzepatide is approved for diabetes as Mounjaro and for weight management as Zepbound. Telehealth providers commonly prescribe compounded versions for weight management without requiring a diabetes diagnosis.
How long do I need to take these medications?
Current evidence suggests that GLP-1 medications are most effective as ongoing treatment. Clinical trials show that most patients regain a significant portion of lost weight after discontinuing the medication. Many providers recommend a long-term maintenance approach, though some patients work with their providers to taper to the lowest effective dose.
What is a dual GIP/GLP-1 agonist?
Tirzepatide is a dual-action medication that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual mechanism is thought to provide additive benefits for blood sugar control, appetite reduction, and weight loss compared to GLP-1-only medications like semaglutide. It is the first FDA-approved drug in this dual-agonist class.